RepliCel partners with industry and academia to collaboratively develop autologous cell therapies that treat functional cellular deficits. These cells, sourced from the hair follicle, have unique applications for treating a variety of musculoskeletal and dermatological conditions.
Shiseido Company, Limited
RepliCel entered into a collaboration and technology transfer agreement with Shiseido, the third largest cosmetics company in the world on its autologous dermal sheath cup cell technology for treating pattern baldness (RCH-01). The agreement gives Shiseido an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea. Shiseido and RepliCel will collaborate on the continued improvement of the technology and will conduct human clinical trials in each of their territories with the goal of commercializing a safe and effective hair regenerative treatment to help those suffering from pattern baldness and thinning hair.
University of British Columbia
RepliCel has a collaborative research agreement with The University of British Columbia, Department of Dermatology and Skin Science to conduct research into the biochemical and functional characteristics of hair follicles.
RepliCel is developing cell therapies targeting a number of conditions associated with cellular deficits. We are actively seeking potential collaboration or licensing opportunities to explore the therapeutic potential of our technologies. To discuss a partnering or collaboration opportunity, please submit your query to email@example.com or call (604) 248.8730.